TITLE

Comparison of Sarns 3M heparin bonded to Duraflo II and control circuits in a porcine model: macro- and microanalysis of thrombi accumulation in circuit arterial filters

AUTHOR(S)
Larson, Douglas F.; Arzouman, David
PUB. DATE
January 2000
SOURCE
Perfusion;Jan2000, Vol. 15 Issue 1, p13
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides information on a study which compared the efficacy of Sarns 3M heparin-bonded circuit to Baxter Duraflo II and untreated control in reducing thrombus formation during heparinization. Materials and methods used in the study; Results and conclusion.
ACCESSION #
2862839

 

Related Articles

  • There's much R.Ph.s can do to improve anticoagulation. Hitchens, Kathy // Drug Topics;11/17/2003, Vol. 147 Issue 22, p36 

    Discusses the role of registered pharmacists in improving inpatient anticoagulation services in the U.S. Increase in the number of patients on anticoagulation and antithrombotic therapy; Management of heparin-induced thrombocytopenia; Ability of a pharmacist-run clinic to provide...

  • Reteplase incompatible with heparin.  // WHO Drug Information;1999, Vol. 13 Issue 4, p239 

    Reports on a precipitation of the Reteplase drug suspected to be due to an incompatibility with heparin when combined in an intravenous solution in European Union countries. Recommended modifications on prescribing and patient information; Other risk from similar incompatibilities.

  • Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Hommes, Daan W.; Bura, Alessandra; Mazzolai, Lucia; Buller, Harry R.; ten Cate, Jan W.; Hommes, D W; Bura, A; Mazzolai, L; B├╝ller, H R; ten Cate, J W // Annals of Internal Medicine;2/15/92, Vol. 116 Issue 4, p279 

    Objective: To quantitatively assess the efficacy and safety of published randomized trials comparing subcutaneous heparin with continuous intravenous heparin for the initial treatment of deep vein thrombosis.Data Identification: Studies published between January 1986...

  • heparin.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1058 

    A definition of the medical term "heparin," which refers to a parenteral anticoagulant drug with a faster onset than warfarin or its derivatives, is presented.

  • What is the Optimal Dosing for Unfractionated Heparin? Scherger, Joseph E. // Internal Medicine Alert;5/15/2007, Vol. 29 Issue 9, p68 

    Clinical guidelines now recommend using prophylaxis against VTE in high risk hospitalized patients. Subcutaneous unfractionated heparin (UH) has become the treatment of choice due to its safety and ease of monitoring and administration. Patients who are commonly treated include any acutely ill...

  • Disseminated Intravascular Coagulation During Heparin Therapy. Klein, Harvey G.; Bell, William R. // Annals of Internal Medicine;Apr74, Vol. 80 Issue 4, p477 

    Proposes mechanisms that might cause or prolong disseminated intravascular coagulation during heparin therapy. Possible cause of disseminated intravascular coagulation; Theory on heparin therapy; Doses of heparin that failed to prevent disseminated intravascular coagulation.

  • Heparin dose during percutaneous coronary intervention: how low dare we go? Niccoli, G.; Banning, A.P. // Heart;Oct2002, Vol. 88 Issue 4, p331 

    Discusses the role and dosage of heparin during percutaneous coronary intervention (PCI). Effects of tradition and habit on dose selection for heparin use in PCI; Reasons why unfractioned heparin remains the standard procedural anticoagulant despite advances in PCI; Implications on cardiology.

  • LMWH as Bridge Anticoagulation During Warfarin Interruption. Miller, Karl E. // American Family Physician;4/15/2005, Vol. 71 Issue 8, p1599 

    Presents an abstract of the study "Molecular-Weight Heparin As Bridging Anticoagulation During Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulant Regimen," by J. D. Douketis and colleagues, published in the June 28, 2004 issue of "Archives of Internal Medicine."

  • Pharmacology and therapeutic applications of hirudin, an new anticoagulant. Glusa, Erika // Kidney International Supplement;Feb98, Issue 64, pS-54 

    Examines the pharmacology and therapeutic applications of hirudin, used for anticoagulant. Functions of hirudin as the most potent direct inhibitor of thrombin; Monitoring on the hirudin effects; Clinical aspects of hirudin therapy.

  • Heparin.  // Reactions Weekly;Mar2015, Vol. 1541 Issue 1, p142 

    An abstract of the article "Acute adrenal insufficiency associated with bilateral adrenal hemorrhage in the course of heparin-induced thrombocytopenia (HIT)," by M. H. Horani and colleagues is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics